乳腺癌 PIK3CA 基因突变与抗 HER2靶向治疗疗效的相关性  

The correlation of PIK3CA gene mutation and the efficacy of anti-HER2 targeted therapy for breast cancer

作　　者：邵喜英[1] 郑亚兵[1] 王晓稼[1] 

机构地区：[1]浙江省肿瘤医院乳腺肿瘤内科,杭州310022

出　　处：《国际肿瘤学杂志》2016年第9期699-702,共4页Journal of International Oncology

基　　金：浙江省自然科学基金（Y2101312）;浙江省重大科技专项（2012C13019-1）;浙江省医药卫生科技计划（2016KYA046、2016RCA003、2015RCB005、2010QNA006）;浙江省医药卫生省部培育计划（2015PYA001）

摘　　要：HER2阳性乳腺癌 PIK3CA 基因突变率高达25％，该基因突变能激活 PI3K-Akt 信号通路并促进 HER2介导的肿瘤细胞上皮转化，改变 HER2过表达肿瘤的内在表型，进而导致抗 HER2靶向治疗耐药。相关研究发现，PIK3CA 基因突变与抗 HER2靶向治疗疗效相关。因此，实时监测 PIK3CA 基因突变状态将有助于实现个体化抗 HER2靶向治疗。It has been shown that the PIK3CA mutation in HER2 positive breast cancer is up to 25%, and thus activates PI3K-Akt signaling pathway,promotes HER2 mediated tumor cell epithelial transformation, alters the intrinsic phenotype of HER2 overexpression breast cancer,and finally leads to resistance to anti HER2 targeted therapy.Some studies have shown that the PIK3CA gene mutation is associated with the efficacy of anti-HER2 targeted therapy.Therefore,real-time monitoring of PIK3CA gene mutation will promote indivi-dualized anti-HER2 targeted therapy.

关 键 词：乳腺肿瘤 受体 表皮生长因子 PIK3CA 基因突变 

分 类 号：R737.9[医药卫生—肿瘤]